Daniel Hood - Achilles Therapeutics General Secretary
| ACHL Stock | USD 1.07 0.02 1.90% |
Executive
Daniel Hood is General Secretary of Achilles Therapeutics PLC
| Address | 245 Hammersmith Road, London, United Kingdom, W6 8PW |
| Phone | 44 20 8154 4600 |
| Web | https://www.achillestx.com |
Achilles Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4422) %, meaning that it created substantial loss on money invested by shareholders. Achilles Therapeutics' management efficiency ratios could be used to measure how well Achilles Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.45. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Achilles Therapeutics' Other Current Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 170.7 M this year, although the value of Other Assets will most likely fall to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard Colonno | Assembly Biosciences | 74 | |
| Robert MBBS | Instil Bio | N/A | |
| Moses Makunje | Nuvation Bio | 45 | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Kevin Shaw | NextCure | 49 | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Amy CFA | Assembly Biosciences | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Udayan MD | NextCure | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| YuWaye MD | CytomX Therapeutics | 56 | |
| Sourav Kundu | NextCure | 63 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Anuj MD | Assembly Biosciences | 46 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 |
Achilles Therapeutics PLC Leadership Team
Elected by the shareholders, the Achilles Therapeutics' board of directors comprises two types of representatives: Achilles Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achilles. The board's role is to monitor Achilles Therapeutics' management team and ensure that shareholders' interests are well served. Achilles Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achilles Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sergio Quezada, Founder Officer | ||
| Daniel Hood, General Secretary | ||
| Tariq Ahmed, Executive People | ||
| James Taylor, Chief Officer | ||
| Julia Wilson, Head Communications | ||
| Lee Stern, Vice Communications | ||
| FMEDSCI MD, Founder | ||
| Karl MD, Founder Officer | ||
| Shree Patel, Executive Operations | ||
| Iraj Ali, CEO Director | ||
| BSc FRCPath, Founder | ||
| Edward Samuel, Executive Operations | ||
| Robert Coutts, Chief Officer |
Achilles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achilles Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (36.74 M) | ||||
| Shares Outstanding | 41.09 M | ||||
| Shares Owned By Insiders | 6.51 % | ||||
| Shares Owned By Institutions | 59.29 % | ||||
| Number Of Shares Shorted | 159.25 K | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.43 X | ||||
| EBITDA | (70.44 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.